Pantethine versus fenofibrate in the treatment of type II hyperlipoproteinemia.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D010204:Pantetheine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D011422:Propionates / Q000627:therapeutic use*; D011897:Random Allocation; D013438:Sulfhydryl Compounds / Q000627:therapeutic use*
D008055:Lipids; D008074:Lipoproteins; D011422:Propionates; D013438:Sulfhydryl Compounds; D010204:Pantetheine; C005425:pantethine; D011345:Fenofibrate